ABSTRACT NUMBER: ESOC2026YS41 EFFECT COMPARISON OF ENZYME INDUCING AGAINST NON ENZYME INDUCING ANTISEIZURE MEDICATIONS AS POTENTIAL CARDIOVASCULAR RISK FACTORS IN PEOPLE LIVING WITH EPILEPSY

Abstract Background and aims Epilepsy is a neurologic condition that affects 10% of the world population, characterized by an augmented risk of presenting seizures, with neurobiological, cognitive, psychological and social consequences. People with epilepsy also present a larger risk of medical and psychiatric comorbidities, among them cardiovascular diseases. The relationship between epilepsy and cardiovascular disease is multifactorial, involving genetic, structural and autonomic mechanisms; traditional modifiable and non-modifiable cardiovascular risk factors are involved as well. Antiseizure medication has been identified as a risk factor, with conflicting evidence concerning if enzymatic induction multiplies the risk. In Costa Rica only two large scale descriptive studies have been developed in people living with epilepsy, with diverging results concerning cardiovascular disease prevalence and the profile of seizure medication prescribed, reflecting a lineal relationship between prescription of enzyme inducing seizure medication and prevalence of cardiovascular disease Methods A descriptive retrospective transversal study is proposed, enrolling an adult population of people diagnosed with epilepsy with outpatient follow up in Tony Facio Hospital during the period of December 2023 to December 2024. Of these patients it will be analized the relationship between enzyme inducing antiseizure medication in comparison with non-enzyme inducing medication and an increased risk for cardiovascular disease development (ischemic cardiopathy, cerebrovascular disease, peripheral artery disease) Results Finishing ethics comitee approval Conflict of interest nothing to disclose